Anticancer Drug Development: Evaluative Architecture

Anticancer drug development is complex and multi-factorial, demanding robust drug evaluative architecture in experimental and preclinical studies. To increase the number of drug licensing, biochemical, pharmacological, technical and economic changes (balance and integration) in evaluative systems should be focused in labs throughout the world. Despite great progress, treatment breakthroughs and drug industry need new ideas and more competitive technology (new generation of in vitro test systems). Overall, drug evaluative systems comprise anticancer drug development (medicinal chemistry and pharmacology) from initial screening to clinical validity. Its advances greatly impact the outcomes of drug production (rates of final drug licensing and efficacy of therapeutics in the clinic). In this regard, creative ideas and new techniques will change the norm and convention of drug screening and mechanic exploration in the future. This article provides multi-disciplinary approaches for experimental and preclinical anticancer drug evaluations, selections and combinations (chemistry and biomedicine). Future trends for drug evaluative systems are especially highlighted in in-depth, multilateral and multidisciplinary approaches.